Knoa Pharma and Amneal Listed as Holders of OxyContin FDA Regulatory Approval Rights and Distribution Partner.
Purdue Pharma's Bankruptcy and the Launch of Knoa Pharma
Purdue Pharma, which underwent bankruptcy proceedings due to the opioid abuse crisis, has been dissolved, and Knoa Pharma LLC, a public-interest entity that inherits its assets and drug manufacturing rights, was officially launched on May 1, 2026. This signifies a transition from Purdue Pharma, a profit-driven pharmaceutical company, to an independent, public-interest entity operating to support opioid prevention and addiction treatment. Knoa Pharma has fully inherited NDA 022272, which holds key rights related to the development and abuse-deterrent formulation of OxyContin (oxycodone hydrochloride), an opioid analgesic.
Amneal Pharmaceuticals Joins as a Generic Distribution Partner
This regulatory record confirms that Amneal Pharmaceuticals (AMRX) has been officially listed as the authorized generic distribution partner for OxyContin. Amneal is a major player in the existing market for generic opioid analgesics, possessing a strong supply chain. Through this partnership, Amneal has secured an exclusive position to distribute abuse-deterrent OxyContin generic products. This demonstrates a strategic collaboration between the two companies to efficiently supply high-quality drugs manufactured by Knoa Pharma to the market, control abuse risks, and secure stable revenues.
Regulatory Significance of Mu-Opioid Receptor Targeting Treatments
OxyContin is an extended-release prescription drug that acts on mu-opioid receptors in the brain and spinal cord, providing potent pain relief. Due to its extremely high risk of abuse, it is classified as a Schedule II controlled substance by the Drug Enforcement Administration (DEA). This FDA database listing is more than just a transfer of rights; it is a crucial regulatory milestone to legally maintain a supply chain for necessary abuse-deterrent analgesics under a public-interest entity, while maintaining strong control.
Opioid Market Restructuring and Industrial Impact
As of 2025, the global oxycodone drug market is estimated at approximately $3.2 billion to $5.7 billion, and it is projected to grow to $9.2 billion by 2035. OxyContin, which recorded annual sales of $2.8 billion at its peak, has maintained annual sales of approximately $1.7 billion in recent years, still accounting for a significant share of the market. This transfer and partnership change represents a restructuring of the existing opioid market, with leadership shifting to a transparent, public-interest manufacturing entity and a proven large generic distributor, presenting a new benchmark model that simultaneously pursues social responsibility and commercial viability.
The establishment of a partnership between Knoa Pharma LLC, a public-interest entity established through Purdue Pharma's bankruptcy agreement, and Amneal Pharmaceuticals (AMRX), a generic pharmaceutical company, is strategically aimed at maintaining a stable supply and regulatory control of the $1.7 billion OxyContin market, which is already approved and marketed. This FDA succession listing marks a formal transition of the supply leadership in the existing opioid analgesic market from Purdue Pharma to the public-interest Knoa Pharma system. In the short term, Amneal's strong distribution network will help defend market share against alternatives such as Collegium's Xtampza ER. In the medium to long term, with the global oxycodone market expected to grow from approximately $3.2 billion to $5.7 billion in 2025 to $9.2 billion by 2035, the successful establishment of the public-interest entity model will be a significant precedent for the governance structure of the broader regulated substance industry.
Source: openFDA (api_fda)
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=NDA022272